Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Fixed drug eruption with interferon-beta-1b.

Yee J Tai1, Mei Tam

  • 1Department of Dermatology, St. Vincent's Hospital, Melbourne, Victoria, Australia. yeejentai@yahoo.com

The Australasian Journal of Dermatology
|July 13, 2005
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Association of Cognitive Flexibility With Negative Emotional States and Quality of Life in Patients With Hidradenitis Suppurativa: A Cross-Sectional Study.

The Australasian journal of dermatology·2025
Same author

A simple solution for habit-tic nail deformity.

The Australasian journal of dermatology·2023
Same author

Scarring in pyoderma gangrenosum.

The Australasian journal of dermatology·2021
Same author

Pentoxifylline as a treatment for granuloma annulare.

The Australasian journal of dermatology·2019
Same author

An update of the pathogenesis of frontal fibrosing alopecia: What does the current evidence tell us?

The Australasian journal of dermatology·2018
Same author

The first Australian Baseline Series: Recommendations for patch testing in suspected contact dermatitis.

The Australasian journal of dermatology·2014

A patient with multiple sclerosis developed a fixed drug eruption from interferon-beta-1b. The rash resolved after discontinuing the medication, highlighting a rare adverse reaction to this multiple sclerosis treatment.

Area of Science:

  • Immunology
  • Dermatology
  • Neurology

Background:

  • Multiple sclerosis (MS) is a chronic autoimmune disease affecting the central nervous system.
  • Interferon-beta-1b is a common disease-modifying therapy for MS.
  • Adverse drug reactions can impact treatment adherence and patient outcomes.

Observation:

  • A 32-year-old female MS patient experienced a fixed drug eruption (FDE).
  • The FDE manifested as non-injection-site-related erythematous plaques.
  • Lesions appeared one month after initiating interferon-beta-1b and worsened with subsequent doses.

Findings:

  • Histopathology confirmed the diagnosis of fixed drug eruption.
  • Discontinuation of interferon-beta-1b led to complete rash resolution within six weeks.

Related Experiment Videos

  • This case demonstrates a rare cutaneous adverse effect of interferon-beta-1b therapy in MS.

    • Implications:

    • Highlights the importance of considering FDE in MS patients on interferon-beta-1b presenting with specific dermatological symptoms.
    • Underscores the need for vigilant monitoring of adverse drug reactions in chronic disease management.
    • Informing differential diagnosis and patient counseling regarding potential side effects of MS treatments.